US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
09. Mai 2024 09:31 ET
|
Spherix Global Insights
Exton, Pennsylvania, May 09, 2024 (GLOBE NEWSWIRE) -- Even as the incidence of Parkinson’s disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape...
Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™
05. Februar 2021 09:00 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
27. Mai 2020 16:30 ET
|
Denali Therapeutics Inc.
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the...
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
27. Februar 2020 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
06. August 2019 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study
05. August 2019 09:00 ET
|
Denali Therapeutics Inc.
Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study.DNL758 is an investigational small molecule RIPK1 inhibitor that does not cross the blood-brain barrier, and is intended for...
Denali Therapeutics Reports First Quarter 2019 Financial Results
08. Mai 2019 16:30 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
12. März 2019 09:00 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
10. Dezember 2018 09:00 ET
|
Denali Therapeutics Inc.
Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:...